The problem of toxoplasmosis in outpatient practice. Part I. Toxoplasmosis in immunocompetent patients

Abstract

Acute toxoplasmosis in immunocompetent persons most often proceeds subclinically and ends with the formation of latent toxoplasmosis, which does not require therapy and observation. The presence of clinical signs of a long-term disease forces an extensive diagnostic search to exclude/confirm chronic toxoplasmosis. In the treatment of toxoplasmosis in persons without immunodeficiency, repeated courses of antiprotozoal drugs are used, which do not guarantee clinical recovery and the absence of relapses. Perinatal aspects of toxoplasmosis will be discussed in a future publication.

Keywords

toxoplasmosis / immunocompetent persons / diagnostics / therapy / family medicine

References

[1] De Lima Bessa G, de Almeida Vitor RW, Dos Santos Martins-Duarte E. Toxoplasma gondii in South America: a differentiated pattern of spread, population structure and clinical manifestations. Parasitol Res. 2021;120(9):3065–3076. DOI: 10.1007/s00436-021-07282-w

[2] De Lima Bessa G., de Almeida Vitor R.W., Dos Santos Martins-Duarte E. Toxoplasma gondii in South America: a differentiated pattern of spread, population structure and clinical manifestations // Parasitol. Res. 2021. Vol. 120, No. 9. P. 3065–3076. DOI: 10.1007/s00436-021-07282-w

[3] Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009;39(8):895–901. DOI: 10.1016/j.ijpara.2009.02.004

[4] Weiss L.M., Dubey J.P. Toxoplasmosis: A history of clinical observations // Int. J. Parasitol. 2009. Vol. 39, No. 8. P. 895–901. DOI: 10.1016/j.ijpara.2009.02.004

[5] Ybañez RHD, Ybañez AP, Nishikawa Y. Review on the current trends of toxoplasmosis serodiagnosis in humans. Front Cell Infect Microbiol. 2020;10:204. DOI: 10.3389/fcimb.2020.00204

[6] Ybañez R.H.D., Ybañez A.P., Nishikawa Y. Review on the current trends of toxoplasmosis serodiagnosis in humans // Front. Cell Infect. Microbiol. 2020. Vol. 10. P. 204. DOI: 10.3389/fcimb.2020.00204

[7] Hajissa K, Zakaria R, Suppian R, Mohamed Z. Design and evaluation of a recombinant multi-epitope antigen for serodiagnosis of Toxoplasma gondii infection in humans. Parasit Vectors. 2015;8:315. DOI: 10.1186/s13071-015-0932-0

[8] Hajissa K., Zakaria R., Suppian R., Mohamed Z. Design and evaluation of a recombinant multi-epitope antigen for serodiagnosis of Toxoplasma gondii infection in humans // Parasit. Vectors. 2015. Vol. 8. P. 315. DOI: 10.1186/s13071-015-0932-0

[9] Robert MG, Brenier-Pinchart MP, Garnaud C, et al. Molecular diagnosis of toxoplasmosis: recent advances and a look to the future. Expert Rev Anti Infect Ther. 2021;19(12):1529–1542. DOI: 10.1080/14787210.2021.1941867

[10] Robert M.G., Brenier-Pinchart M.P., Garnaud C. et al. Molecular diagnosis of toxoplasmosis: recent advances and a look to the future // Expert. Rev. Anti. Infect. Ther. 2021. Vol. 19, No. 12. P. 1529–1542. DOI: 10.1080/14787210.2021.1941867

[11] Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120(10):911.e1–8. DOI: 10.1016/j.amjmed.2006.12.011

[12] Hurt C., Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses // Am. J. Med. 2007. Vol. 120, No. 10. P. 911.e1–8. DOI: 10.1016/j.amjmed.2006.12.011

[13] Liu KY, Chao HM, Lu YJ, et al. Cytomegalovirus proctitis in non-human immunodeficiency virus infected patients: A case report and literature review. J Microbiol Immunol Infect. 2022;55(1):154–160. DOI: 10.1016/j.jmii.2021.10.002

[14] Liu K.Y., Chao H.M., Lu Y.J. et al. Cytomegalovirus proctitis in non-human immunodeficiency virus infected patients: A case report and literature review // J. Microbiol. Immunol. Infect. 2022. Vol. 55, No. 1. P. 154–160. DOI: 10.1016/j.jmii.2021.10.002

[15] Beder D, Esenkaya Taşbent F. General features and laboratory diagnosis of toxoplasma gondii infection. Turkiye Parazitol Derg. 2020;44(2):94–101. DOI: 10.4274/tpd.galenos.2020.6634

[16] Beder D., Esenkaya Taşbent F. General features and laboratory diagnosis of toxoplasma gondii infection // Turkiye Parazitol. Derg. 2020. Vol. 44, No. 2. P. 94–101. DOI: 10.4274/tpd.galenos.2020.6634

[17] Brenier-Pinchart MP, Filisetti D, Cassaing S, et al. Molecular diagnosis of toxoplasmosis: Multicenter evaluation of the toxoplasma realcycler universal PCR assay on 168 characterized human samples. J Mol Diagn. 2022;24(6):687–696. DOI: 10.1016/j.jmoldx.2022.03.009

[18] Brenier-Pinchart M.P., Filisetti D., Cassaing S. et al. Molecular diagnosis of toxoplasmosis: Multicenter evaluation of the toxoplasma realcycler universal PCR assay on 168 characterized human samples // J. Mol. Diagn. 2022. Vol. 24, No. 6. P. 687–696. DOI: 10.1016/j.jmoldx.2022.03.009

[19] Neves ES, Espíndola OM, Curi A, et al. PCR-based diagnosis is not always useful in the acute acquired toxoplasmosis in immunocompetent individuals. Parasitol Res. 2021;120(2):763–767. DOI: 10.1007/s00436-020-07022-6

[20] Neves E.S., Espíndola O.M., Curi A. et al. PCR-based diagnosis is not always useful in the acute acquired toxoplasmosis in immunocompetent individuals // Parasitol. Res. 2021. Vol. 120, No. 2. P. 763–767. DOI: 10.1007/s00436-020-07022-6

[21] Lobzin YuV, Vasiliev VV. Priobretennii toxoplazmoz: kriterii diagnostoki i printsipy terapii. Rossiiskii meditsinskii zhurnal. 2001;2:43–45. (In Russ.)

[22] Лобзин Ю.В., Васильев В.В. Приобретенный токсоплазмоз: критерии диагностики и принципы лечения // Российский медицинский журнал. 2001. № 2. С. 43–45.

[23] Fabiani S, Caroselli C, Menchini M, et al. Ocular toxoplasmosis, an overview focusing on clinical aspects. Acta Trop. 2022;225:106180. DOI: 10.1016/j.actatropica.2021.106180

[24] Fabiani S., Caroselli C., Menchini M. et al. Ocular toxoplasmosis, an overview focusing on clinical aspects // Acta Trop. 2022. Vol. 225. P. 106180. DOI: 10.1016/j.actatropica.2021.106180

[25] Patel NS, Vavvas DG. Ocular toxoplasmosis: a review of current literature. Int Ophthalmol Clin. 2022;62(2):231–250. DOI: 10.1097/IIO.0000000000000419

[26] Patel N.S., Vavvas D.G. Ocular toxoplasmosis: a review of current literature // Int. Ophthalmol. Clin. 2022. Vol. 62, No. 2. P. 231–250. DOI: 10.1097/IIO.0000000000000419

[27] Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022;42(1):295–321. DOI: 10.1007/s10792-021-01994-9

[28] Kalogeropoulos D., Sakkas H., Mohammed B. et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches // Int. Ophthalmol. 2022. Vol. 42, No. 1. P. 295–321. DOI: 10.1007/s10792-021-01994-9

[29] Feliciano-Alfonso JE, Muñoz-Ortiz J, Marín-Noriega MA, et al. Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis. Syst Rev. 2021;10(1):206. DOI: 10.1186/s13643-021-01758-7

[30] Feliciano-Alfonso J.E., Muñoz-Ortiz J., Marín-Noriega M.A. et al. Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis // Syst. Rev. 2021. Vol. 10, No. 1. P. 206. DOI: 10.1186/s13643-021-01758-7

[31] Suzuki Y. A pathway to cure chronic infection with Toxoplasma gondii through immunological intervention. Parasitol Int. 2021;81:102259. DOI: 10.1016/j.parint.2020.102259

[32] Suzuki Y. A pathway to cure chronic infection with Toxoplasma gondii through immunological intervention // Parasitol. Int. 2021. Vol. 81. P. 102259. DOI: 10.1016/j.parint.2020.102259

[33] Vasiliev VV, Romanova ES. Laboratory examination for toxoplasmosis: indications, Methods and results’ interpretation. Russian family doctor. 2014;18(3):4–9. (In Russ.) DOI: 10.17816/RFD201434-9

[34] Васильев В.В., Романова Е.С. Лабораторное обследование на токсоплазмоз: показания, методы, интерпретация результатов // Российский семейный врач. 2014. Т. 18, № 3. C. 4–9. DOI: 10.17816/RFD201434-9

[35] Catchpole A, Zabriskie BN, Bassett P, et al. Association between toxoplasma gondii Infection and type-1 diabetes mellitus: a systematic review and meta-analysis. Int J Environ Res Public Health. 2023;20(5):4436. DOI: 10.3390/ijerph20054436

[36] Catchpole A., Zabriskie B.N., Bassett P. et al. Association between toxoplasma gondii Infection and type-1 diabetes mellitus: a systematic review and meta-analysis // Int. J. Environ. Res. Public Health. 2023. Vol. 20, No. 5. P. 4436. DOI: 10.3390/ijerph20054436

[37] Yin K, Xu C, Zhao G, Xie H. Epigenetic manipulation of psychiatric behavioral disorders induced by Toxoplasma gondii. Front Cell Infect Microbiol. 2022;12:803502. DOI: 10.3389/fcimb.2022.803502

[38] Yin K., Xu C., Zhao G., Xie H. Epigenetic manipulation of psychiatric behavioral disorders induced by toxoplasma gondii // Front. Cell Infect. Microbiol. 2022. Vol. 12. P. 803502. DOI: 10.3389/fcimb.2022.803502

[39] Bassett P, Zabriskie BN, Catchpole A, Hedges D. Association between Toxoplasma gondii and systemic lupus erythematosus: A systematic review and meta-analysis. J Transl Autoimmun. 2022;5:100163. DOI: 10.1016/j.jtauto.2022.100163

[40] Bassett P., Zabriskie B.N., Catchpole A., Hedges D. Association between Toxoplasma gondii and systemic lupus erythematosus: A systematic review and meta-analysis // J. Transl. Autoimmun. 2022. Vol. 5. P. 100163. DOI: 10.1016/j.jtauto.2022.100163

[41] Daher D, Shaghlil A, Sobh E, et al. Comprehensive overview of toxoplasma gondii-induced and associated diseases. Pathogens. 2021;10(11):1351. DOI: 10.3390/pathogens10111351

[42] Daher D., Shaghlil A., Sobh E. et al. Comprehensive overview of toxoplasma gondii-induced and associated diseases // Pathogens. 2021. Vol. 10, No. 11. P. 1351. DOI: 10.3390/pathogens10111351

[43] Holec-Gąsior L, Sołowińska K. IgG avidity test as a tool for discrimination between recent and distant toxoplasma gondii infection-current status of studies. Antibodies (Basel). 2022;11(3):52. DOI: 10.3390/antib11030052

[44] Holec-Gąsior L., Sołowińska K. IgG avidity test as a tool for discrimination between recent and distant Toxoplasma gondii infection – current status of studies // Antibodies (Basel). 2022. Vol. 11, No. 3. P. 52. DOI: 10.3390/antib11030052

[45] Zhao XY, Ewald SE. The molecular biology and immune control of chronic Toxoplasma gondii infection. J Clin Invest. 2020;130(7):3370–3380. DOI: 10.1172/JCI136226

[46] Zhao X.Y., Ewald S.E. The molecular biology and immune control of chronic Toxoplasma gondii infection // J. Clin. Invest. 2020. Vol. 130, No. 7. P. 3370–3380. DOI: 10.1172/JCI136226

[47] Álvarez García G, Davidson R, Jokelainen P, et al. Identification of oocyst-driven toxoplasma gondii infections in humans and animals through stage-specific serology-current status and future perspectives. Microorganisms. 2021;9(11):2346. DOI: 10.3390/microorganisms9112346

[48] Álvarez García G., Davidson R., Jokelainen P. et al. Identification of oocyst-driven Toxoplasma gondii infections in humans and animals through stage-specific serology-current status and future perspectives // Microorganisms. 2021. Vol. 9, No. 11. P. 2346. DOI: 10.3390/microorganisms9112346

[49] Vasiliev VV, Timchenko VN, Vasillieva IS. Ratsionalnaya terapiya toxoplazmoza. Detskie infektsii. 2004;3:42–46. (In Russ.)

[50] Васильев B.В., Тимченко В.Н., Васильева И.С. Рациональная терапия токсоплазмоза // Детские инфекции. 2004. № 3. С. 42–46.

[51] Lobzin YuV, Kalinina NM, Vasiliev VV, Sysoev KA. Immunomodulation by toxoplasmin in chronic toxoplasmosis treatment. Meditsinskaya immunologiya. 2000;2(3):299–304. (In Russ.)

[52] Лобзин Ю.В., Калинина Н.М., Васильев В.В., Сысоев К.А. Иммуномодуляция токсоплазмином в лечении хронического токсоплазмоза // Медицинская иммунология. 2000. Т. 2, № 3. С.299–304.

RIGHTS & PERMISSIONS

Eco-Vector